Sustainable Development for the Healthcare Industry: Reprogramming the Healthcare Value Chain (Perspectives on Sustainable Growth)

This volume addresses the dynamics of sustainable development in the healthcare industry, covering all major aspects, including R&D, manufacturing, regulation, market access, commercialization, and general management.  Healthcare markets are evolving under demographic and economic pressures. In mature markets, patients navigate complex systems with limited control on healthcare quality and outcomes, while in developing markets, patients have limited awareness, access, and ability to pay for healthcare. The industry needs to identify which business targets are genuinely attractive for major or new investments.

 

At the same time, development of new  products and services must be tackled within the context of environmental sustainability. Rather than focusing on the traditional issues of innovation, cost management, and commercial effectiveness associated with growth, the authors explore such emerging topics as:

• The mutations of innovation management
• The need to foster patient-centricity along the entire value chain of the healthcare industry and company-wide
• Issues related to improving healthcare access and disease management
• The allocation of educational resources focused on the patient to increase the effectiveness of disease management
• The preservation of natural resources and the environmental effect of pollution and hazards created by the handling of pharmaceutical products
• Issues related to the size of medical need and/or market demand
• The private-public partnerships necessary to address the full spectrum of public health issues, from basic patient access to care to managing global health crises
• The required organizational and governance evolutions for the healthcare industry to maintain profitability and sustainablegrowth.

Featuring contributions from leading academics and industry insiders with emphasis on environmental, economically, and socially sustainable practices, the authors present a unique, multi-faceted set of perspectives on this vital and rapidly evolving field.

Pierre A. Morgon is Chief Marketing Officer and member of the Executive Committee at Cegedim. He is also Non-Executive Director to the Board of Theradiag since March 2012, a company focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy, as well as Non-Executive Director to the Board of Eurocine Vaccines since December 2013, a company dedicated to developing nasal vaccines.

He holds a Doctorate of Pharmacy from Lyon University, France, a Master in Business Law from the Lyon Law School and a MBA from ESSEC, France. He is also an alumnus of INSEAD, IMD and MCE executive programs.

Pierre has over 26 years of experience in the pharmaceutical and biological industry, both in marketing positions (from product marketing at country level to global marketing strategy) and in operations (from business unit head to general manager).  Through these local and global positions, he has acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology), geographies (US, Europe, Japan, China, India, Emerging Markets) and organizations.

He spent 2 years at ICI-Pharma, followed by 8 years at Synthelabo, then a division of L’Oreal. He joined Aventis Pasteur in 1998, then he had diversified experiences in operations at Yamanouchi Pharma, BMS, Drug Abuse Sciences, Schering-Plough and Bio Alliance Pharma. He joined Cegedim from Sanofi Pasteur where he was Vice President, Franchise & Global Marketing Strategy and member of the Executive Committee.